Utah Medical Products (NASDAQ:UTMD) and Hancock Jaffe Laboratories (NASDAQ:HJLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.
Volatility & Risk
Utah Medical Products has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Hancock Jaffe Laboratories has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
Valuation & Earnings
This table compares Utah Medical Products and Hancock Jaffe Laboratories’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Utah Medical Products||$46.90 million||6.50||$14.73 million||N/A||N/A|
|Hancock Jaffe Laboratories||$30,000.00||173.09||-$7.63 million||N/A||N/A|
Utah Medical Products has higher revenue and earnings than Hancock Jaffe Laboratories.
This table compares Utah Medical Products and Hancock Jaffe Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Utah Medical Products||31.40%||14.81%||13.40%|
|Hancock Jaffe Laboratories||N/A||-263.14%||-139.10%|
Insider and Institutional Ownership
74.5% of Utah Medical Products shares are held by institutional investors. Comparatively, 1.3% of Hancock Jaffe Laboratories shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by insiders. Comparatively, 6.4% of Hancock Jaffe Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for Utah Medical Products and Hancock Jaffe Laboratories, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Utah Medical Products||0||0||0||0||N/A|
|Hancock Jaffe Laboratories||0||0||1||0||3.00|
Hancock Jaffe Laboratories has a consensus price target of $3.00, indicating a potential upside of 1,011.11%. Given Hancock Jaffe Laboratories’ higher probable upside, analysts clearly believe Hancock Jaffe Laboratories is more favorable than Utah Medical Products.
Utah Medical Products beats Hancock Jaffe Laboratories on 8 of the 11 factors compared between the two stocks.
Utah Medical Products Company Profile
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry in the United States, Europe, and internationally. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system. It also provides umbilical vessel catheters; DIALY-NATE, a disposable peritoneal dialysis set; PALA-NATE, a silicone oral protection device; URI-CATH, a urinary drainage system; MYELO-NATE, a lumbar sampling kit; and HEMO-NATE, a disposable filter. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars and cannulae; Femcare laparoscopic instruments and accessories; and EPITOME, an electrosurgical scalpel. Further, it provides FILSHIE CLIP system, a female surgical contraception; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization; LIBERTY system to treat and control urinary incontinence in women; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other suspected abnormalities of the uterus; and LUMIN to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It markets its products to neonatal intensive care unit, labor and delivery department, women's health center in hospitals, outpatient clinics, and physician's offices. The company sells its products through customer service and sales force, independent consultants, and independent manufacturer representatives. Utah Medical Products, Inc. was founded in 1978 and is headquartered in Midvale, Utah.
Hancock Jaffe Laboratories Company Profile
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.